Faculty Documentation

Faculty Documentation

Faculty Information

This information below will be used in our program materials. Please indicate how you would like it to appear including name, degree(s), title(s), and affiliation(s).

Upload Bio/CV File or Write Your Own?

Maximum file size: 2MB

Maximum file size: 2MB

The information below will be used for program planning.

Program Information

*By signing this agreement, I understand that this session may be recorded. I also understand that the content developed for the program may be repurposed and utilized in an Enduring Web Activity with my permission.

Proposed Learning Objectives

After participating in these activities, learners will be better able to:

  • Participants will be able to evaluate the efficacy and safety of using PARP inhibitors in managing HRR-mutated metastatic prostate cancer, including potential side effects and monitoring parameters.
  • Participants can review the latest guidelines and recommendations for peri-operative therapy in localized rectal cancer.
  • Participants will identify the role and significance of biomarkers in early and advanced-stage non-small cell lung cancer
  • Discuss current and future roles of newly approved targeted therapies in all breast cancer subtypes
  • Understand the side effects of practice-changing novel therapies and their integration into community practice
  • Discuss emerging strategies for patients with platinum-resistant ovarian cancer
  • Discuss the optimal strategies for the use of CAR T Cell and bispecific T-cell engagers in Diffuse Large B Cell Lymphoma 
  • Explain how to optimize treatment selection in Multiple Myeloma, including the use of bispecific T- Cell engagers
  • Identify novel treatment approaches in Acute Lymphoblastic and Acute Myeloid Leukemia

After completing this activity, participants will be able to:

  • Review the recent developments in breast surgical approaches, including upfront and after neoadjuvant chemotherapy, including the decision-making approach to axillary interrogation.
  • Discuss the disparities encountered and identified in the breast cancer patient.
    Explain the rationale for reconstruction options post neoadjuvant chemotherapy and radiation therapy.
  • Discuss updates in breast cancer imaging for earlier detection.
  • Explore the understanding of subsets of aggressive breast pathology and molecular profiling.
  • Identify therapeutic advances in early and advanced hormone receptor-positive, HER2 neu overexpressing, and triple-negative breast cancer.
  • Review the advances in radiation therapy and outcomes, including short-course radiation therapy and de-escalation, and who may not need radiation therapy in breast conservation.
  • Describe the management of HER2-positive early breast cancer in the older patient and
  • Understand the psychosocial, histologic and treatment disparities of the older breast cancer patient.
  • Understanding genetic mutations and approach to treatment.
  • Identify the new and emerging systemic treatment options for breast cancer brain metastases beyond surgery and radiotherapy.
  • Understanding the science and therapeutic options using molecular profiling for patients with breast cancer.
  • Explain the mechanism of action and rationale for immunotherapy.
  • Discussing the psychosocial health of the oncology health provider.
  • Updates on nutritional health for patients with early and advanced breast cancer.
  • Bone health and when and when not to intervene
I agree with the terms of this Agreement.

Faculty Guidelines:

  • Present current and clinically relevant information to meet the stated objectives.
  • Provide a balanced view of the topic area; be objective when reporting research; and disclose unlabeled use of drugs/products where applicable.
  • Discuss the safety and adverse effects of drugs/products presented.
  • Inform myMedEd if you anticipate new applications or changes to the FDA status of a presented product, which may impact the planned content during the course approval period.
  • Include case studies where applicable.
  • Support assertions and clinical studies with references where applicable.
  • Faculty members are responsible for accuracy and completeness of references as well as obtaining permission to reproduce any copyrighted materials. Provide copies of correspondence granting permission.
  • myMedEd will notify faculty of the program deadline(s). The content requested must be received on or before the deadline date given.